Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CMMB.NASDAQ

Chemomab Therapeutics Ltd DRC (CMMB NASDAQ) stock market data APIs

$1.34 0.07(5.5%) as of July 26, 2024
Price chart is built with Anychart

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics Ltd DRC Financial Data Overview

1.27
1.34
-
1.34
1.2224
0.42-1.58
18 343 K
14 219 K
0
-0.2753
0.2
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CMMB',
Type: 'Common Stock',
Name: 'Chemomab Therapeutics Ltd DRC',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00N0PMGK1',
ISIN: NULL,
CUSIP: NULL,
CIK: '1534248',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2019-02-12',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Chemomab Therapeutics Ltd DRC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -20 390 250
  • Earnings Per Share -1.54
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Chemomab Therapeutics Ltd DRC Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -0.03

Get Chemomab Therapeutics Ltd DRC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Chemomab Therapeutics Ltd DRC latest news via APIs

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis— —Chemomab's CCL24-Neutralizing Antibody CM-...
  • CHEMOMAB THERAPEUTICS
  • CLINICAL TRIALS
  • DISEASE ACTIVITY
  • FORWARD-LOOKING STATEMENTS
  • INFLAMMATORY DISEASES
  • LIVER FIBROSIS
  • PROFESSOR FRANCESCO DEL GALDO
  • SERUM LEVELS
  • SYSTEMIC SCLEROSIS
  • THERAPEUTIC TARGET

54 Biggest Movers From Yesterday

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares climbed 356.8% to close at $45.50 on Thursday following an announcement the company will merge with Trump Media & Technology Group. Port...
  • INC
  • NASDAQ
  • NYSE
  • THERAPEUTICS INC
  • TRISTATE CAPITAL HOLDINGS
Do you have any questions?
support@eodhistoricaldata.com